Valneva SE (EPA:VLA)
2.966
+0.040 (1.37%)
Aug 21, 2026, 5:35 PM CET
Valneva SE Revenue
Valneva SE had revenue of 34.94M EUR in the quarter ending June 30, 2026, a decrease of -27.71%. This brings the company's revenue in the last twelve months to 142.94M, down -27.19% year-over-year. In the year 2025, Valneva SE had annual revenue of 174.66M with 3.00% growth.
Revenue (ttm)
142.94M
Revenue Growth
-27.19%
P/S Ratio
3.94
Revenue / Employee
230.55K
Employees
620
Market Cap
562.49M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 174.66M | 5.08M | 3.00% |
| Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | 126.20M | 13.16M | 11.64% |
| Dec 31, 2018 | 113.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Genfit | 70.85M |
| Cellectis | 55.86M |
| Nanobiotix | 32.59M |
| MedinCell | 24.28M |
| Innate Pharma | 9.01M |
| Transgene | 7.21M |
| Inventiva | 6.76M |
| Sensorion | 5.81M |
Valneva SE News
- 7 days ago - Pfizer, Valneva announce EMA validation for PF-07307405 MAA - TheFly
- 9 days ago - Valneva Stock (VLN) Soars Over 20% On Lyme Disease Vaccine Hopes - TipRanks
- 9 days ago - Pfizer And Valneva's Lyme Vaccine Clears EMA Review Gate - Nasdaq
- 9 days ago - Pfizer, Valneva's Lyme Disease Vaccine Application Validated By EMA - Nasdaq
- 9 days ago - Pfizer Inc.: Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency - Finanz Nachrichten
- 9 days ago - Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency - GlobeNewsWire
- 9 days ago - Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency - Wallstreet:Online
- 9 days ago - Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency - Business Wire